Skip to content

Study on the relationship between anlotinib combined with docetaxel therapy and intestinal flora evolution in non-small cell lung cancer

Study on the relationship between anlotinib combined with docetaxel therapy and intestinal flora evolution in non-small cell lung cancer

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500098959
Enrollment
Unknown
Registered
2025-03-17
Start date
2025-03-17
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

Sponsors

The Second Hospital of Dalian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Voluntarily participate in the study, fully understand and know about the study and sign the informed consent; Patients with primary non-small cell lung cancer with clear histological and pathological evidence; Aged 18-80 years old (inclusive); ECOG score is less than 2 points; Patients with non-small cell lung cancer who have progressed after prior systemic chemotherapy; may have CT or MRI evaluate the lesion and have at least one evaluation result; During the study, patients were advised to stop smoking and drinking, and avoid spicy and irritating food.

Exclusion criteria

Exclusion criteria: Exclude patients with autoimmune diseases and digestive diseases; Patients with secondary primary malignancy were excluded; Antibiotics, laxative drugs, immunosuppressants, microecological preparations and other treatments within 1 month are excluded of patients; Patients with infectious diseases such as viral hepatitis, HIV and syphilis are excluded; High-dose hormonal treatment is required in the near term, active brain metastases require treatment, meninges metastases.

Design outcomes

Primary

MeasureTime frame
Progression-free survival;

Secondary

MeasureTime frame
Objective Response Rate;Disease control rate;Duration of remission;Time to progression;Overall survival;

Countries

China

Contacts

Public ContactChen Jun

The Second Hospital of Dalian Medical University

chenjundl@vip.sina.com+86 177 0987 3616

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026